Ex vivo gene transfer into myocardium using replication-defective retrovirus

Area of Science:

• Cardiovascular Biology
• Regenerative Medicine
• Gene Therapy

Background:

• Heart transplantation is a vital treatment for end-stage heart failure.
• A significant shortage of donor hearts limits transplantation efficacy.
• Investigating alternative strategies like genetically modified cell transplantation is crucial.

Purpose of the Study:

• To assess the feasibility of genetically modifying cardiomyocytes before transplantation.
• To determine if these modified cells can be successfully grafted into the heart.
• To evaluate the long-term gene expression and host response post-transplantation.

Main Methods:

• Utilized a replication-defective retrovirus carrying the beta-galactosidase (beta-gal) reporter gene for genetic modification.
• Transduced murine fetal cardiac myocytes and sorted positive cells using fluorescence-activated cell sorting (FACS).
• Transplanted genetically modified cardiomyocytes into syngeneic adult mice and assessed gene expression via X-gal staining.

Main Results:

• Successfully transduced 25.5% +/- 4.3% of cardiomyocytes with the beta-gal gene.
• Demonstrated sustained beta-gal gene expression in grafted cells for up to 6 months post-transplantation.
• Histological analysis revealed no inflammation or fibrous scar tissue in the host myocardium.

Conclusions:

• Genetically modified cardiac cells can be successfully transplanted into the heart.
• This approach shows potential for future cardiac regenerative therapies.
• Sustained gene expression and absence of adverse host reactions support the viability of this method.